“IQVIA. ai enables organisations to move faster and smarter while meeting the rigorous standards of trust and reliability that are required in the industry”
Bernd Haas SVP of AI & Technology Solutions IQVIA
IQVIA is transforming how pharmaceutical companies develop clinical trials and ultimately, bring new drugs to market.
Its capabilities span almost every stage of clinical development to accelerate drug development, including AI-assisted protocol design, patient recruitment optimisation, investigator site selection and decentralised clinical trials.
IQVIA’ s AI strategy has accelerated in 2026, reinforcing its position as a leading digital transformation partner for the pharmaceutical industry.
In March, the company launched IQVIA. ai, an agentic AI platform developed with NVIDIA that combines proprietary healthcare data with AI agents and automation to support research, clinical development, regulatory affairs and commercial operations.
Commenting on the launch, Bernd Haas, SVP of AI & Technology Solutions at IQVIA, describes how the company is accelerating digital transformation:“ By bringing together our data, expertise and Healthcare-grade AI within a unified, agentic platform, IQVIA. ai enables organisations to move faster and smarter while meeting the rigorous standards of trust and reliability that are required in the industry.”
A month earlier, IQVIA expanded its footprint in drug discovery by acquiring Charles River Laboratories’ discovery assets, extending its capabilities further upstream in the R & D process.
The company has also deepened AI-enabled partnerships, including a collaboration with Kexing Biopharm to accelerate biosimilar development.
healthcare-digital. com 87